Form 144 filing: An insider of Zai Lab Ltd. (ZLAB), identified as Yajing Chen, notifies intent to sell 4,096 American Depositary Shares (ADS) through Fidelity on or after 08 Aug 2025. The block is valued at roughly US$139,305 based on current market pricing.
The shares were acquired on 25 Jun 2024 via restricted-stock vesting as compensation. Chen has already sold 9,618 ADS (US$288,540) on 02 Jun 2025 and 2,675 ADS (US$96,652) on 26 Jun 2025, bringing recent disposals to 12,293 ADS, or about US$385,192 in proceeds.
Planned and recent sales combined equal 16,389 ADS—just 0.0039% of the 421.7 million shares outstanding—indicating a negligible impact on ownership structure or float. The document contains no operational or financial performance data; it is strictly a regulatory notice of a small insider sale, which may signal mild negative sentiment but is unlikely to move the stock on size alone.
Zai Lab Limited (ZLAB) Q2 2025 10-Q highlights: Net product revenue rose 9 % YoY to $109.1 million, lifting total revenue to $110.0 million. Cost controls drove a 28 % YoY cut in operating loss to $54.9 million and shrank net loss by 49 % to $40.7 million (-$0.04/share). Six-month revenue climbed 15 % to $216.5 million, with net loss down 33 % to $89.2 million.
Growth came from VYVGART (+14 %), NUZYRA (+16 %), XACDURO and AUGTYRO launches, partly offset by a 9 % decline in ZEJULA. R&D expense fell 18 % YoY, SG&A fell 11 %, and operating cash outflow improved to -$92.7 million from -$132.3 million. Cash & equivalents surged to $732.2 million after maturing $330 million of short-term investments; short-term debt increased to $174.5 million (2.66 % avg. rate).
- Q2 gross margin ~61 % (product revenue vs. cost of product revenue).
- Shares outstanding: 1.10 billion; ADS float 421.7 million.
- Pivotal pipeline events: Fast Track for ZL-1310 (SCLC), positive Phase III data for bemarituzumab (FGFR2b gastric), PANOVA-3 success for TTFields, NMPA sNDA acceptance for repotrectinib.
- Subsequent event: doubled CMB revolving facility to RMB500 million (~$69.6 million) on 6 Aug 2025.
Despite stronger top-line momentum and disciplined spending, Zai Lab remains loss-making and dependent on capital markets and credit lines while advancing an expansive late-stage pipeline.
Zai Lab Limited (NASDAQ: ZLAB) filed a Form 144 indicating that insider Ying Du plans to sell 7,072 American Depositary Shares (ADS) on 02 July 2025 through Fidelity Brokerage Services. The proposed transaction is valued at US$249,143.73, representing roughly 0.0015 % of the company’s 486.9 million ADS outstanding, and stems from the vesting of restricted stock on 01 July 2025.
The filing also discloses that the same insider has already sold 235,729 ADS between 02 April 2025 and 30 June 2025, generating an estimated US$7.1 million in gross proceeds. These prior sales were executed in eight tranches ranging from 2,945–50,000 ADS each.
Although the absolute dollar value of the individual sale is modest relative to Zai Lab’s market capitalization, the cumulative selling pattern may be interpreted by some investors as a signal of insider profit-taking. No new operational, earnings or strategic information is provided in this filing; the document is strictly a regulatory notice satisfying Rule 144 requirements.
Zai Lab (NASDAQ:ZLAB) filed a Form 4 revealing that Chief Legal Officer Edmondson Frazor Titus III’s 14,600 RSUs vested on 25 Jun 2025, converting into the same number of ADSs.
To cover withholding taxes, he sold 5,877 ADSs on 26 Jun 2025 at $36.132 (≈ $213 k), coded “S”. Post-transaction, his direct stake stands at 44,975 ADSs, each ADS representing ten ordinary shares.
The sale, while automatic under a Rule 10b5-1 plan, equals roughly 12 % of his pre-sale position, crossing the 5 % materiality threshold and offering investors a governance data-point rather than a directional signal.